MFG
LPCN icon

Merit Financial Group’s Lipocine LPCN Stock Holding History

Merit Financial Group’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,759
Closed -$11.9K – 680
2022
Q4 		$11.9K Hold
1,759
– – ﹤0.01% 684
2022
Q3 		$13K Hold
1,759
– – ﹤0.01% 565
2022
Q2 		$24K Buy
+1,759
New +$27.4K ﹤0.01% 559

Other funds holding LPCN

EWA
EP Wealth Advisors Torrance, California $20.3B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Merit Financial Group's LPCN Position: Q1 2023 in Review

Merit Financial Group sold out of Lipocine (LPCN) in Q1 2023, closing a stake of 1,759 shares — an estimated $11.9K sold.

Merit Financial Group first reported a position in LPCN in Q2 2022 and held it in 3 quarters. The position peaked at $24K in Q2 2022. 45 funds tracked by Wall St. Rank hold LPCN as of Q1 2023.

  • Merit Financial Group reported no remaining Lipocine position as of Q1 2023 after selling out during the quarter.
  • Merit Financial Group sold 1,759 Lipocine shares in Q1 2023, an estimated $11.9K.
  • Merit Financial Group first reported a position in Lipocine in Q2 2022 and held it in 3 quarters.
  • Merit Financial Group's Lipocine position peaked at $24K in Q2 2022.
  • 45 funds tracked by Wall St. Rank held Lipocine as of Q1 2023.

Based on Merit Financial Group's 13F filing for Q1 2023, filed 24 Apr 2023.